Asher Bio Closes $108 Million Series B Financing

02 Sep, 2021

Asher Bio Closes $108 Million Series B Financing
Photo by Leohoho on Unsplash

– Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of an oversubscribed Series B financing, which raised $108m.
– The financing was led by Wellington Management Company, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors.

Biotechnology North America Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: